Sep 12, 2023 / 08:15PM GMT
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity Analyst
Hey, guys, good afternoon. My name is Tejas Savant, and I'm the Life Science, Tools and Diagnostics Analyst here at Morgan Stanley. Before we begin, for important disclosures, please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your sales rep.
It's my pleasure this afternoon to host Veracyte. And speaking on behalf of the company, we have Marc Stapley, CEO; and Rebecca Chambers, CFO. So thanks, guys, for doing this.
Marc, maybe to start, you've been in your seat for about a year now. What do you view as Veracyte's key accomplishments since you took charge? And what are you most excited about heading into 2024?
Marc A. Stapley - Veracyte, Inc. - CEO & Director
Yes. And thanks very much for having us both here again. And maybe before I start, I'd just like to make my own statement regarding today, we may be making forward-looking statements. So I would refer everybody to
Veracyte Inc at Morgan Stanley Global Healthcare Conference Transcript
Feb 29, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers